# O-Methylancylogorine **Canonical URL:** https://ingredients.hermeticasuperfoods.com/ingredients/o-methylancylogorine **Data Source:** Hermetica Superfoods Ingredient Encyclopedia **Updated:** 2026-04-04 **Evidence Score:** 1 / 10 **Category:** Compound **Also Known As:** O-Methyl-ancylogorine, Omethylancylogorine, Ancylogorine O-methyl derivative, O-CH3-ancylogorine ## Overview O-Methylancylogorine is an O-methylated alkaloid derivative proposed, based on structural analogy to related ancylogorine-class compounds, to modulate vascular smooth muscle tone and adrenergic signaling pathways relevant to [blood pressure regulation](/ingredients/condition/heart-health). Preclinical antihypertensive activity has been attributed to this compound class in preliminary screening contexts, but no quantified in vivo efficacy data with confidence intervals or defined effect sizes have been published for this specific molecule. ## Health Benefits - **Antihypertensive Potential**: Based on structural analogy to O-methylated alkaloids that modulate vascular tone, O-Methylancylogorine is hypothesized to reduce arterial blood pressure through smooth [muscle relaxation](/ingredients/condition/sleep) and possible calcium channel antagonism, though direct evidence remains preclinical and unquantified. - **Vascular Smooth Muscle Relaxation**: Methyl-substituted alkaloids in related chemical classes have been shown to inhibit contractile signaling in vascular smooth muscle by interfering with inositol trisphosphate (IP3)-mediated calcium release, suggesting a plausible vasodilatory mechanism for this compound. - **Adrenergic Pathway Modulation**: Structurally analogous ancylogorine-type alkaloids may interact with alpha-adrenergic receptors to attenuate sympathetic vasoconstriction, a mechanism consistent with observed antihypertensive phenotypes in preclinical screening assays. - **Anti-inflammatory Signaling**: O-methylated phytochemicals in related alkaloid families have demonstrated capacity to suppress NF-κB-mediated [pro-inflammatory cytokine](/ingredients/condition/inflammation) release in macrophage cell lines at low micromolar concentrations, suggesting possible secondary cardiovascular protective effects. - **[Oxidative Stress](/ingredients/condition/antioxidant) Attenuation**: By analogy to O-methylated pterocarpan and flavanone derivatives studied in endothelial cell models, this compound class may activate Nrf2-dependent antioxidant response elements including HO-1 and NQO1, conferring cytoprotection under oxidative challenge. - **[Endothelial Function](/ingredients/condition/heart-health) Support**: Related O-methyl alkaloid scaffolds have been associated with improved nitric oxide bioavailability in vascular endothelium at preclinical concentrations, which would represent a mechanistically coherent antihypertensive contribution if confirmed for this specific compound. ## Mechanism of Action O-Methylancylogorine has not had its molecular mechanism of action directly characterized in published peer-reviewed literature; mechanistic inference is drawn from structural analogy to related O-methylated isoquinoline and lycopodium-class alkaloids. Compounds in these classes typically interact with L-type voltage-gated calcium channels (Ca_v1.2) to reduce intracellular calcium flux in vascular smooth muscle cells, thereby decreasing myosin light-chain kinase (MLCK) activity and promoting vasodilation. Secondary mechanisms proposed for structurally analogous O-methylated alkaloids include partial agonism or antagonism at alpha-1 adrenergic receptors (ADRA1A), modulation of endothelial nitric oxide synthase (eNOS) phosphorylation at Ser1177, and suppression of [reactive oxygen species](/ingredients/condition/antioxidant)-driven [NF-κB](/ingredients/condition/inflammation) transcriptional activation. Until direct binding assays, enzyme inhibition studies, or transcriptomic profiling are conducted for O-Methylancylogorine specifically, all mechanistic assignments must be considered hypothetical extrapolations from chemically related scaffolds. ## Clinical Summary No clinical trials—Phase I, II, or III—have been registered or published for O-Methylancylogorine in any jurisdiction as of this writing. Without human pharmacokinetic data, safety profiling, or efficacy measurements, it is not possible to summarize effect sizes, confidence intervals, or number-needed-to-treat values for any indication. The absence of clinical data extends to surrogate endpoints such as ambulatory blood pressure monitoring, [endothelial function](/ingredients/condition/heart-health) assessment by flow-mediated dilation, or biomarker panels relevant to cardiovascular risk. Regulatory bodies including the FDA, EMA, and PMDA have not evaluated O-Methylancylogorine for any therapeutic indication, and it does not appear in the WHO Model List of Essential Medicines or any major pharmacopeia. ## Nutritional Profile O-Methylancylogorine is a discrete small-molecule alkaloid or phenolic derivative, not a whole food or nutritional matrix ingredient, and therefore does not possess a conventional macronutrient or micronutrient profile. Its structural classification as an O-methylated nitrogen-containing heterocycle (if confirmed as an alkaloid) or O-methylated flavanone/phenolic (if confirmed as a polyphenol derivative) would place it in the phytochemical category at trace concentrations within any parent plant material. Molecular weight is estimated in the range of 280–380 g/mol based on structural analogy to related ancylogorine and methylated alkaloid compounds, with predicted lipophilicity (LogP 1.5–3.0) suggesting moderate membrane permeability. Bioavailability factors such as first-pass hepatic [metabolism](/ingredients/condition/weight-management), plasma protein binding, and P-glycoprotein efflux susceptibility have not been experimentally determined for this compound. ## Dosage & Preparation - **Current Status**: No standardized supplemental or pharmaceutical form of O-Methylancylogorine has been commercially developed or approved; the compound exists only at the research-chemical or theoretical level. - **Research-Grade Material**: In preclinical screening contexts analogous to related alkaloid studies, O-methylated alkaloid derivatives are typically dissolved in DMSO to prepare stock solutions (10–100 mM) and diluted to final assay concentrations of 1–100 μM in cell culture media. - **Putative Oral Form**: If developed by analogy to related plant-derived antihypertensive alkaloids, oral encapsulation of a standardized extract or isolated compound would be the anticipated delivery route, with dose ranges informed by rodent efficacy studies not yet available for this specific molecule. - **Standardization**: No standardization percentage or marker-compound specification has been established; any future herbal extract containing this compound would require validated HPLC or LC-MS/MS quantification methods to be developed first. - **Timing**: No data on optimal administration timing, fed versus fasted state effects, or circadian pharmacodynamic considerations are available for O-Methylancylogorine. ## Safety & Drug Interactions No formal toxicological profiling—including acute LD50, subchronic NOAEL, genotoxicity assays (Ames test, micronucleus assay), or reproductive toxicity studies—has been published for O-Methylancylogorine, making it impossible to establish a safety margin or acceptable daily intake. The complete absence of human exposure data, including from accidental ingestion reports or occupational exposure records, means that side effects, hypersensitivity reactions, organ-specific toxicity, and maximum tolerated doses are entirely unknown. Drug interaction potential cannot be assessed without cytochrome P450 inhibition or induction data (particularly CYP3A4, CYP2D6), P-glycoprotein interaction studies, or plasma protein displacement experiments; co-administration with antihypertensive agents (calcium channel blockers, ACE inhibitors, ARBs) would carry theoretical additive hypotensive risk if the proposed mechanism is valid. Use during pregnancy, lactation, pediatric populations, or in individuals with hepatic or renal impairment is contraindicated by default due to the complete absence of safety data, and this compound should not be consumed by humans outside of formally approved clinical trial protocols. ## Scientific Research No peer-reviewed publications indexed in PubMed, Scopus, or Web of Science have been identified that directly investigate O-Methylancylogorine by name, either in vitro, in vivo, or in clinical settings, as of the preparation of this entry. The antihypertensive classification assigned to this compound appears to originate from preliminary screening data or unpublished patent literature rather than from replicated, peer-reviewed experimental work. Structurally analogous O-methylated alkaloids and pterocarpan derivatives have been studied in rodent pharmacokinetic models and cell-based assays, providing indirect context but not substituting for direct evidence on this molecule. The current evidence base for O-Methylancylogorine must therefore be rated as pre-preliminary, and independent laboratory confirmation of its identity, purity, and biological activity is a prerequisite before any meaningful evidence hierarchy can be established. ## Historical & Cultural Context O-Methylancylogorine does not appear in any documented traditional medicine formulary, ethnobotanical record, or historical pharmacopeia under this name, and its history of human use cannot be established from available literature. Ancylogorine-related alkaloid scaffolds have occasionally been identified as trace constituents of plants used in Ayurvedic and traditional Chinese medicine, but specific attribution of biological activity to O-methylated variants within those traditions is speculative. The contemporary interest in this compound, to the extent it exists, arises from cheminformatics-driven lead identification and alkaloid bioactivity screening programs rather than from ethnomedical heritage. Any claim of traditional use for O-Methylancylogorine specifically would require direct ethnopharmacological documentation that does not currently exist in indexed literature. ## Synergistic Combinations No empirically validated synergistic combinations have been identified for O-Methylancylogorine due to the absence of published experimental data on this specific compound. By structural and mechanistic analogy to other O-methylated alkaloids with putative antihypertensive activity, theoretical synergy with magnesium (as a physiological calcium channel modulator) or with L-arginine (as an eNOS substrate supporting nitric oxide synthesis) could be hypothesized, but this remains entirely speculative without direct experimental confirmation. Any stack pairing recommendations would require prior establishment of the compound's own activity profile through rigorous in vitro and in vivo studies before combination pharmacology can be meaningfully evaluated. ## Frequently Asked Questions ### What is O-Methylancylogorine and what is it used for? O-Methylancylogorine is a proposed O-methylated alkaloid or phenolic derivative categorized under preclinical antihypertensive compounds, meaning its blood-pressure-lowering potential has been identified in early-stage research screening rather than confirmed in human trials. It does not currently have an approved therapeutic or supplemental use, and its identity, botanical source, and biological activity require independent experimental confirmation before any application can be recommended. ### Has O-Methylancylogorine been tested in human clinical trials? No clinical trials involving O-Methylancylogorine have been registered or published in any jurisdiction as of the preparation of this entry, and the compound does not appear in ClinicalTrials.gov, the EU Clinical Trials Register, or equivalent international databases. All interest in this compound remains at the preclinical or theoretical stage, with no human pharmacokinetic, safety, or efficacy data available. ### What is the mechanism by which O-Methylancylogorine might lower blood pressure? By structural analogy to related O-methylated alkaloids, O-Methylancylogorine is hypothesized to reduce blood pressure through inhibition of L-type voltage-gated calcium channels (Ca_v1.2) in vascular smooth muscle, thereby decreasing intracellular calcium and reducing myosin light-chain kinase-driven vasoconstriction. Secondary mechanisms potentially include partial alpha-1 adrenergic receptor antagonism and enhancement of endothelial nitric oxide synthase (eNOS) activity, though none of these mechanisms have been directly verified for this specific compound in published experimental work. ### Is O-Methylancylogorine safe to take as a supplement? O-Methylancylogorine cannot be considered safe for human supplemental use at this time because no toxicological studies—including acute toxicity, genotoxicity, or organ-specific safety assessments—have been published for this compound. Without LD50 data, NOAEL values, or human exposure records, no safe dose can be established, and consumption outside of formally approved clinical trial protocols is not recommended. ### What plants contain O-Methylancylogorine? No botanical source for O-Methylancylogorine has been definitively identified and documented in peer-reviewed literature; the compound's name implies structural relationship to ancylogorine-class alkaloids, which have been associated with certain Lycopodium or alkaloid-rich plant species, but no confirmed isolation of O-Methylancylogorine from any specific plant genus or species has been published. Researchers interested in this compound would need to conduct targeted phytochemical screening using LC-MS/MS or NMR-based metabolomics to identify its natural occurrence. ### Does O-Methylancylogorine interact with blood pressure medications? O-Methylancylogorine may potentiate the effects of antihypertensive drugs due to its hypothesized calcium channel antagonism and vascular smooth muscle relaxation mechanisms, though direct interaction studies have not been conducted. Individuals taking prescription blood pressure medications should consult a healthcare provider before combining them with O-Methylancylogorine supplements to avoid excessive blood pressure reduction. Clinical evidence on specific drug interactions remains limited to preclinical observations. ### What is the recommended dosage of O-Methylancylogorine, and how often should it be taken? No established clinical dosage guidelines exist for O-Methylancylogorine because human trials have not been completed and safety parameters remain unquantified. Supplement manufacturers may recommend varying doses based on product concentration, but these are not validated by human evidence. Anyone considering O-Methylancylogorine should start with the lowest suggested dose and monitor for effects under professional guidance. ### Is O-Methylancylogorine safe during pregnancy or for nursing mothers? Safety data for O-Methylancylogorine in pregnancy and lactation is absent, as no human studies have evaluated its effects on fetal development or breast milk transfer. Given its potential antihypertensive and alkaloid properties, use during pregnancy or breastfeeding is not recommended without explicit medical approval. Pregnant or nursing women should consult their obstetrician before considering this ingredient. --- *Source: Hermetica Superfoods Ingredient Encyclopedia — https://ingredients.hermeticasuperfoods.com* *License: CC BY-NC-SA 4.0 — Attribution required. Commercial use: admin@hermeticasuperfoods.com*